|Articles|July 21, 2017
GB Sciences Signs Consulting Services Agreement with Worldwide Clinical Trials, Inc.
Advertisement
GB Sciences, Inc. announced it has signed a consulting services agreement with Worldwide Clinical Trials, Inc. to assess the company's intellectual property portfolio and help with pre-IND planning for its cannabis-based formulations. Pre-IND consulting services will be performed by Michael F. Murphy, MD, PhD, chief medical and scientific officer (CMSO) of Worldwide Clinical Trials, Inc.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research
2
Breaking the Efficacy Ceiling in IBD and Beyond
3
ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program
4
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
5